| Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO) |
39 |
| Copper deficiency anemia: review article |
29 |
| Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation |
20 |
| A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia |
18 |
| Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review |
17 |
| Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO) |
15 |
| Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial |
15 |
| Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors |
15 |
| Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study |
14 |
| Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy |
14 |
| Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo |
13 |
| Consensus statement for cancer patients requiring intensive care support |
13 |
| Thromboembolic events in polycythemia vera |
12 |
| Long non-coding RNA taurine-upregulated gene 1 correlates with poor prognosis, induces cell proliferation, and represses cell apoptosis via targeting aurora kinase A in adult acute myeloid leukemia |
12 |
| Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma |
12 |
| The co-occurrence of driver mutations in chronic myeloproliferative neoplasms |
11 |
| Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the ConnectA (R) MM Registry |
11 |
| PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas |
11 |
| Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group |
11 |
| Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma |
11 |
| Navigating the treatment landscape in multiple myeloma: which combinations to use and when? |
11 |
| Glucocorticoids in multiple myeloma: past, present, and future |
10 |
| Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation |
10 |
| Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016 |
10 |
| Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma |
10 |
| Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients |
10 |
| Transformed follicular lymphoma |
10 |
| Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4) |
9 |
| Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim |
9 |
| Cardiac complications and iron overload in beta thalassemia major patientsa systematic review and meta-analysis |
9 |
| Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria |
9 |
| Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw |
9 |
| Unmet supportive care needs of haematological cancer survivors: rural versus urban residents |
9 |
| A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs |
9 |
| Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia |
9 |
| National registry of hemoglobinopathies in Greece: updated demographics, current trends in affected births, and causes of mortality |
8 |
| Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study |
8 |
| Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia |
8 |
| Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes |
8 |
| Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma |
8 |
| The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience |
8 |
| Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies |
8 |
| Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy |
8 |
| Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma |
8 |
| Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma |
8 |
| Donor-derived marrow mesenchymal stromal cell co-transplantation following a haploidentical hematopoietic stem cell transplantation trail to treat severe aplastic anemia in children |
8 |
| CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations |
8 |
| The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT |
8 |
| The leukemia strikes back: a review of pathogenesis and treatment of secondary AML |
8 |
| Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation |
7 |
